Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sofie, Alverlind"'
Autor:
Raj Tummala, Stéphane Barassin, Steven M. Toler, Sofie Alverlind, Yan Li, Hans Eriksson, Per Dalén
Publikováno v:
Clinical Drug Investigation. 34:457-465
Dexmecamylamine (TC-5214) is a nicotinic channel modulator that was evaluated as a potential adjunct treatment to an antidepressant for patients with major depressive disorder. Dexmecamylamine is almost completely eliminated via the kidneys, with mor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0ffc8992e3eab98cb1f75698ab38ccf
https://doi.org/10.1007/s40261-014-0195-0
https://doi.org/10.1007/s40261-014-0195-0
Autor:
Steven M. Toler, Hongmei Xu, Nidal Al-Huniti, Jessica S. Beaver, Raj Tummala, Sofie Alverlind, Anja Henningsson
Publikováno v:
The Journal of Clinical Pharmacology. 54:707-718
TC-5214 (dexmecamylamine) is a nicotinic channel modulator that has previously been evaluated for treatment of major depression disorder (MDD) and is currently being evaluated by Targacept as a treatment for overactive bladder. A comprehensive popula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17b6eac57fe33e1c9bb0feb224f86a3b
https://doi.org/10.1002/jcph.264
https://doi.org/10.1002/jcph.264
Publikováno v:
Clinical Pharmacology & Therapeutics. 88:532-539
In order to evaluate their potential effects on cardiac repolarization, all new drugs must undergo clinical electrocardiographic evaluation in a thorough QT/QTc (TQT) study. AZD3480, a central nervous system–selective, neuronal nicotinic receptor (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a966c134de3e8ffff187213c0f61adb
https://doi.org/10.1038/clpt.2010.131
https://doi.org/10.1038/clpt.2010.131
Autor:
Hongmei, Xu, Anja, Henningsson, Sofie, Alverlind, Raj, Tummala, Steven, Toler, Jessica S, Beaver, Nidal, Al-Huniti
Publikováno v:
Journal of clinical pharmacology. 54(6)
TC-5214 (dexmecamylamine) is a nicotinic channel modulator that has previously been evaluated for treatment of major depression disorder (MDD) and is currently being evaluated by Targacept as a treatment for overactive bladder. A comprehensive popula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::efd6b09424489977e947937aeae054f1
https://pubmed.ncbi.nlm.nih.gov/24408516
https://pubmed.ncbi.nlm.nih.gov/24408516
Autor:
Emma Boström, John Öhd, Sofie Alverlind, Karl-Gustav Jostell, Sara Lindholm, Björn Paulsson, Kristina Claeson Bohnstedt, Hans-Goran Hardemark, Gunilla Huledal
Publikováno v:
Clinical pharmacology in drug development. 3(1)
AZD1446 is a highly selective agonist of central α4β2 and α2β2 neuronal nicotinic receptors. The compound has been shown to improve cognition in preclinical studies and thus has potential for treatment of cognitive disorders, including Alzheimer'
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab56bbc7d058078e56500855cf4cacd1
https://pubmed.ncbi.nlm.nih.gov/27128232
https://pubmed.ncbi.nlm.nih.gov/27128232